-
UK trial finds propofol remains preferred ICU sedation agent
The recent A2B trial found that neither dexmedetomidine nor clonidine are superior to propofol and may increase risks of agitation and bradycardia.
Recent News
-
The emerging role of biologic therapy in asthma-COPD overlap
Biologics such as dupilumab, mepolizumab, benralizumab, and tezepelumab are an emerging option for select patients with asthma-COPD overlap, particularly those with T2-high inflammatory phenotypes.
-
Update on the evaluation and management of interstitial lung abnormalities
New guidelines from ATS outline the screening and follow-up procedures for interstitial lung abnormalities as well as define who is at higher risk for progressing to ILD.
-
Bridging Specialties program tackles NTM pulmonary disease and bronchiectasis
CHEST launched Bridging Specialties®: Timely Diagnosis for NTM Pulmonary Disease and Bronchiectasis as a way for PCPs and pulmonologists to collaborate and provide earlier and accurate diagnoses.
-
Top reads from the CHEST journal portfolio – July 2025
Editorial Board members share their insights on journal articles about ato-pima effects on OSA, ccFTD usage after coronary artery bypass grafting, and bronchoscopy in nonintubated patients prior to BAE.
-
COURSE trial shows importance of biomarker testing in COPD
While overall the trial was negative, Meilan King Han, MD, MS, and Sanjay Ramakrishnan, MBBS, PhD, said it demonstrated the promise of tezepelumab for patients with baseline blood eosinophil counts ≥ 150 cells/µL.
-
Procalcitonin levels may guide antibiotic duration in patients with suspected sepsis
Paul Dark, MD, PhD, said a 10% reduction in duration of antibiotic use shown in a recent study may seem small, but in the context of antibiotic stewardship, a 10% reduction is important.
